Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-inhaler triple therapy versus open triple therapy for severe COPD in Alagoas
RBR-566h57pRecruiting
- Sponsor
- Universidade Federal de Alagoas
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of umeclidinium, fluticasone, vilanterol, tiotropium, olodaterol and 1 more in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Universidade Federal de Alagoas. Started Jul 2026; status: recruiting.
02
Drugs
umeclidiniumfluticasonevilanteroltiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on RBR-566h57p.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-566h57p.